# From bench to bedside: unlocking the anti-inflammatory, antioxidant, and anticancer promise of curcumin in gynecology

**Authors:** Nazlı Tunca Sanlier, Koray Gorkem Sacinti, İnci Turkoglu, Nevin Sanlier

PMC · DOI: 10.3389/fmed.2026.1761721 · Frontiers in Medicine · 2026-02-20

## TL;DR

This review explores curcumin's potential as a treatment for gynecological cancers and conditions, highlighting its anti-inflammatory, antioxidant, and anticancer properties.

## Contribution

The paper synthesizes current evidence and molecular mechanisms of curcumin in gynecology, emphasizing its therapeutic promise and challenges.

## Key findings

- Curcumin modulates inflammatory pathways and reduces oxidative stress in gynecologic disorders.
- Improved curcumin formulations show better pharmacokinetic profiles and therapeutic outcomes.
- More clinical trials are needed to optimize curcumin's use in gynecologic care.

## Abstract

Curcumin, a bioactive polyphenol derived from turmeric (Curcuma longa), has garnered substantial attention for its potent anti-inflammatory, antioxidant, and antineoplastic properties. This review explores the therapeutic potential of curcumin in gynecologic health, with a focus on its role in the management of ovarian, cervical, and endometrial cancers, as well as benign conditions such as endometriosis, polycystic ovary syndrome, premenstrual syndrome, and menopausal symptoms. A literature review was conducted on the health effects of gynecology. Relevant articles were identified through systematic searches in major biomedical databases, including PubMed, Scopus, Cochrane Library, Embase, and Web of Science databases for studies reporting the relationship between curcumin and some in gynecological diseasess as of 2025. Curcumin modulates key inflammatory signaling pathways, reduces oxidative stress, and exerts antiproliferative effects, making it a promising adjunct in the treatment of both neoplastic and inflammatory gynecologic disorders. Nevertheless, clinical translation remains limited by challenges such as poor bioavailability and a paucity of large-scale, randomized controlled trials. Emerging evidence supports the integration of curcumin into multimodal treatment strategies, particularly in oncology and chronic inflammatory conditions. In light of the need to improve treatment efficacy and enhance patients’ quality of life, the exploration of novel adjuvant therapeutic strategies is highly warranted. Recent studies have demonstrated the beneficial effects of curcumin and its novel analogues across a range of gynecologic diseases, while advances in formulation technologies have led to improved pharmacokinetic profiles and therapeutic outcomes. Nevertheless, further robust clinical investigations are required to optimize curcumin formulations, enhance bioavailability, and establish evidence-based guidelines for its integration into gynecologic care. This review synthesizes current evidence and highlights the underlying molecular mechanisms responsible for the observed effects, aiming to support the rational development of curcumin-based strategies in gynecology.

## Linked entities

- **Chemicals:** curcumin (PubChem CID 969516)
- **Diseases:** ovarian cancer (MONDO:0005140), cervical cancer (MONDO:0002974), endometrial cancer (MONDO:0002447), endometriosis (MONDO:0005133), polycystic ovary syndrome (MONDO:0008487), premenstrual syndrome (MONDO:0004169)
- **Species:** Curcuma longa (taxon 136217)

## Full-text entities

- **Genes:** PPARG (peroxisome proliferator activated receptor gamma) [NCBI Gene 5468] {aka CIMT1, FPLD3, GLM1, NR1C3, PPARG1, PPARG2}, EGFR (epidermal growth factor receptor) [NCBI Gene 1956] {aka ERBB, ERBB1, ERRP, HER1, NISBD2, NNCIS}, PIK3CB (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta) [NCBI Gene 5291] {aka P110BETA, PI3K, PI3KBETA, PIK3C1}, TRPM2 (transient receptor potential cation channel subfamily M member 2) [NCBI Gene 7226] {aka EREG1, KNP3, LTRPC2, LTrpC-2, NUDT9H, NUDT9L1}, CXCR4 (C-X-C motif chemokine receptor 4) [NCBI Gene 7852] {aka CD184, D2S201E, FB22, HM89, HSY3RR, LCR1}, CCND1 (cyclin D1) [NCBI Gene 595] {aka BCL1, D11S287E, PRAD1, U21B31}, HIF1A (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 3091] {aka HIF-1-alpha, HIF-1A, HIF-1alpha, HIF1, HIF1-ALPHA, MOP1}, CXCL12 (C-X-C motif chemokine ligand 12) [NCBI Gene 6387] {aka IRH, PBSF, SCYB12, SDF1, TLSF, TPAR1}, LEP (leptin) [NCBI Gene 3952] {aka LEPD, OB, OBS}, CDH1 (cadherin 1) [NCBI Gene 999] {aka Arc-1, BCDS1, CD324, CDHE, ECAD, LCAM}, PTK2B (protein tyrosine kinase 2 beta) [NCBI Gene 2185] {aka CADTK, CAKB, FADK2, FAK2, PKB, PTK}, SLIT2 (slit guidance ligand 2) [NCBI Gene 9353] {aka SLIL3, Slit-2}, PLEKHM3 (pleckstrin homology domain containing M3) [NCBI Gene 389072] {aka DAPR, PLEKHM1L}, HSD17B13 (hydroxysteroid 17-beta dehydrogenase 13) [NCBI Gene 345275] {aka FLDP, HMFN0376, NIIL497, SCDR9, SDR16C3}, MAPK1 (mitogen-activated protein kinase 1) [NCBI Gene 5594] {aka ERK, ERK-2, ERK2, ERT1, MAPK2, NS13}, CRP (C-reactive protein) [NCBI Gene 1401] {aka PTX1}, ALDH1A1 (aldehyde dehydrogenase 1 family member A1) [NCBI Gene 216] {aka ALDC, ALDH-E1, ALDH1, ALDH11, HEL-9, HEL-S-53e}, IL6 (interleukin 6) [NCBI Gene 3569] {aka BSF-2, BSF2, CDF, HGF, HSF, IFN-beta-2}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, KEAP1 (kelch like ECH associated protein 1) [NCBI Gene 9817] {aka INrf2, KLHL19}, SP1 (Sp1 transcription factor) [NCBI Gene 6667], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, BCL2 (BCL2 apoptosis regulator) [NCBI Gene 596] {aka Bcl-2, PPP1R50}, SLC17A5 (solute carrier family 17 member 5) [NCBI Gene 26503] {aka AST, ISSD, NSD, SD, SIALIN, SIASD}, ncRNA [NCBI Gene 54719], CAT (catalase) [NCBI Gene 847], TGFB1 (transforming growth factor beta 1) [NCBI Gene 7040] {aka CAEND1, CED, DPD1, IBDIMDE, LAP, TGF-beta1}, CTNNB1 (catenin beta 1) [NCBI Gene 1499] {aka CTNNB, EVR7, MRD19, NEDSDV, armadillo}, NFE2L2 (NFE2 like bZIP transcription factor 2) [NCBI Gene 4780] {aka IMDDHH, NRF2, Nrf-2}, SOD1 (superoxide dismutase 1) [NCBI Gene 6647] {aka ALS, ALS1, HEL-S-44, IPOA, SOD, STAHP}, NFKB1 (nuclear factor kappa B subunit 1) [NCBI Gene 4790] {aka CVID12, EBP-1, KBF1, NF-kB, NF-kB1, NF-kappa-B1}, CASP3 (caspase 3) [NCBI Gene 836] {aka CPP32, CPP32B, SCA-1}, IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, CASP9 (caspase 9) [NCBI Gene 842] {aka APAF-3, APAF3, ICE-LAP6, MCH6, PPP1R56}, ZHX2 (zinc fingers and homeoboxes 2) [NCBI Gene 22882] {aka AFR1, RAF}, MMP2 (matrix metallopeptidase 2) [NCBI Gene 4313] {aka CLG4, CLG4A, MMP-2, MMP-II, MONA, TBE-1}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, LDLR (low density lipoprotein receptor) [NCBI Gene 3949] {aka LDLCQ2}, INSR (insulin receptor) [NCBI Gene 3643] {aka CD220, HHF5}, MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, KCNK2 (potassium two pore domain channel subfamily K member 2) [NCBI Gene 3776] {aka K2p2.1, TPKC1, TREK, TREK-1, TREK1, hTREK-1c}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, CYP19A1 (cytochrome P450 family 19 subfamily A member 1) [NCBI Gene 1588] {aka ARO, ARO1, CPV1, CYAR, CYP19, CYPXIX}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}, NOS2 (nitric oxide synthase 2) [NCBI Gene 4843] {aka HEP-NOS, INOS, NOS, NOS2A}, NOTCH1 (notch receptor 1) [NCBI Gene 4851] {aka AOS5, AOVD1, TAN1, hN1}, JUN (Jun proto-oncogene, AP-1 transcription factor subunit) [NCBI Gene 3725] {aka AP-1, AP1, c-Jun, cJUN, p39}, STAT3 (signal transducer and activator of transcription 3) [NCBI Gene 6774] {aka ADMIO, ADMIO1, APRF, HIES}, BAX (BCL2 associated X, apoptosis regulator) [NCBI Gene 581] {aka BCL2L4}, AQP3 (aquaporin 3 (Gill blood group)) [NCBI Gene 360] {aka AQP-3, GIL}, AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}, TNFSF10 (TNF superfamily member 10) [NCBI Gene 8743] {aka APO2L, Apo-2L, CD253, TANCR, TL2, TNLG6A}, PTGS2 (prostaglandin-endoperoxide synthase 2) [NCBI Gene 5743] {aka COX-2, COX2, GRIPGHS, PGG/HS, PGHS-2, PHS-2}, MIR320A (microRNA 320a) [NCBI Gene 407037] {aka MIRN320, MIRN320A, hsa-mir-320a, mir-320a}, IGHE (immunoglobulin heavy constant epsilon) [NCBI Gene 3497] {aka IgE}, IL10 (interleukin 10) [NCBI Gene 3586] {aka CSIF, GVHDS, IL-10, IL10A, TGIF}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, INS (insulin) [NCBI Gene 3630] {aka IDDM, IDDM1, IDDM2, ILPR, IRDN, MODY10}, COX2 (cytochrome c oxidase subunit II) [NCBI Gene 4513] {aka COII, MTCO2}, AR (androgen receptor) [NCBI Gene 367] {aka AIS, AR8, DHTR, HPCX3, HUMARA, HYSP1}
- **Diseases:** estrogen (MESH:D056828), gynecologic diseases (MESH:D005831), depression (MESH:D003866), endometrial hyperplasia (MESH:D004714), Ovarian cancer (MESH:D010051), Menopause (MESH:D008594), metastasis (MESH:D009362), related symptoms (MESH:D012816), hyperandrogenism (MESH:D017588), deaths (MESH:D003643), endometrial cancer (MESH:D016889), PCOS (MESH:D011085), dysmenorrhea (MESH:D004412), pelvic pain (MESH:D017699), atherosclerotic (MESH:D050197), EC (MESH:D005955), colorectal cancer (MESH:D015179), cardiovascular disease (MESH:D002318), gynecologic malignancies (MESH:D005833), endocrine disorder (MESH:D004700), anovulatory infertility (MESH:D007246), endometrial, ovarian, cervical, primary peritoneal, vulvar, and vaginal cancers (MESH:D010538), gastrointestinal upsets (MESH:D005767), cytotoxicity (MESH:D064420), insulin resistance (MESH:D007333), mood disturbances (MESH:D019964), obese (MESH:D009765), endometriotic lesions (MESH:D009059), tumorigenesis (MESH:D063646), epithelial ovarian cancer (MESH:D000077216), reproductive toxicity (MESH:D060737), disorders (MESH:D009358), SCID (MESH:D053632), endometrial, cervical, and ovarian cancers (MESH:D002575), Premenstrual syndrome (MESH:D011293), cholangitis (MESH:D002761), Inflammation (MESH:D007249), multifactorial diseases (MESH:D004194), metabolic disturbances (MESH:D024821), cervical and endometrial cancers (MESH:D002583), pain (MESH:D010146), Endometriosis (MESH:D004715), Gynecologic cancers (MESH:D009369), diabetes (MESH:D003920), anxiety (MESH:D001007), EMT (MESH:D002277), NOD (MESH:D020191)
- **Chemicals:** polyphenol (MESH:D059808), GSH (MESH:D005978), lipid (MESH:D008055), dopamine (MESH:D004298), nivolumab (MESH:D000077594), TBARS (MESH:D017392), serotonin (MESH:D012701), glucose (MESH:D005947), ROS (MESH:D017382), cisplatin (MESH:D002945), CUR-M (-), Curcumin (MESH:D003474), doxorubicin (MESH:D004317), letrozole (MESH:D000077289), piperine (MESH:C008922), malondialdehyde (MESH:D008315), curcuminoid (MESH:D036381), phospholipid (MESH:D010743), iron (MESH:D007501), HO-3867 (MESH:C541427), cholesterol (MESH:D002784), nitric oxide (MESH:D009569), glucuronide (MESH:D020719), vitamin D (MESH:D014807), DAPs (MESH:C041756), E2 (MESH:D004958), bilirubin (MESH:D001663), MDA (MESH:D015104), vitamin E (MESH:D014810), cortisol (MESH:D006854), prostaglandin (MESH:D011453)
- **Species:** Curcuma longa (turmeric, species) [taxon 136217], Danio rerio (leopard danio, species) [taxon 7955], Homo sapiens (human, species) [taxon 9606], Ephedra sinica (cao ma-huang, species) [taxon 33152], Mus musculus (house mouse, species) [taxon 10090]
- **Mutations:** A1C
- **Cell lines:** RL-952 — Homo sapiens (Human), Endometrial adenosquamous carcinoma, Cancer cell line (CVCL_0505), HeLa — Homo sapiens (Human), Human papillomavirus-related endocervical adenocarcinoma, Cancer cell line (CVCL_0030), A2780 — Homo sapiens (Human), Ovarian endometrioid adenocarcinoma, Cancer cell line (CVCL_0134), SK-OV-3 — Homo sapiens (Human), Ovarian serous cystadenocarcinoma, Cancer cell line (CVCL_0532), Me180 — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_1401), Ishikawa — Homo sapiens (Human), Type I endometrial adenocarcinoma, Cancer cell line (CVCL_2529), EC — Oncorhynchus tshawytscha (Chinook salmon), Spontaneously immortalized cell line (CVCL_DG46), SiHa — Homo sapiens (Human), Human papillomavirus-related cervical squamous cell carcinoma, Cancer cell line (CVCL_0032), Hec-1B — Homo sapiens (Human), Type II endometrial adenocarcinoma, Cancer cell line (CVCL_0294)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12963359/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12963359/full.md

## References

180 references — full list in the complete paper: https://tomesphere.com/paper/PMC12963359/full.md

---
Source: https://tomesphere.com/paper/PMC12963359